INS and Hypoglycemia: Furthermore, a recent meta-analysis, including 24 RCTs, reported that these long-acting insulin analogs exhibited a reduced risk of severe hypoglycemia compared to NPH (insulin glargine versus NPH: relative risk 0.68, 95% CI 0.46 to 1.01; insulin detemir versus NPH: relative risk 0.45, 95% CI 0.17 to 1.20) [11].